sunitinib
Commercial- Indications
- Gastrointestinal stromal tumor, Renal cell carcinoma, Pancreatic neuroendocrine tumor
Company intelligence / Profile preview
Shilpa Pharma Lifesciences Ltd. and its parent company, Shilpa Medicare Limited, are leading Indian pharmaceutical manufacturers specializing in high-quality Active Pharmaceutical Ingredients (APIs) and finished formulations. The company has a strong focus on oncology but also supplies non-oncology APIs globally. It operates multiple world-class manufacturing facilities with approvals from major regulatory agencies such as USFDA, EUGMP, TGA, PMDA, Cofepris, Anvisa and KFDA. Notable achievements include being the first to obtain generic approval for Lenvatinib Capsules in India and launching branded generics like Dasatinib after patent expiry. The company offers comprehensive CDMO services alongside its own product pipeline.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shilpa Pharma.